AstraZeneca's $1 billion variety first imitated and temporarily approved by hualuohaizheng pharmaceutical

On October 16, Haizheng pharmaceutical announced that its holding subsidiary, Haizheng Hangzhou company, had obtained temporary approval for the Anda (American generic drug application) of tegrilol tablets declared to the US FDA According to the data of minenet, the original research enterprise of tegrilol is AstraZeneca, with the global sales volume of USD 1.079 billion in 2017 At present, there is no imitated product in the market Table 1: basic information of drugs (source: announcement of listed companies) Figure 1: global sales of tegrilol tablets of AstraZeneca from 2014 to 2017 (unit: million US dollars) (source: sales database of Mnet multinational listed companies) the original drug of tegrilol tablets was developed by AstraZeneca and is applicable to the treatment of acute coronary syndrome According to the data of minenet, the global sales of tegrilol in 2017 has exceeded US $1079 million According to the announcement of Haizheng Pharmaceutical Co., Ltd., tegrilol (90mg) is the first imitation application submitted by the company to the US FDA The temporary approval number of the US FDA indicates that the product can only be sold in the US market after the patent expires and the final approval of the FDA The temporary approval number of tegrilol tablets from FDA marks the further promotion of the company's business in the field of generic drugs, which has a positive impact on the company's expansion of the U.S market Up to now, the company has invested about 11 million yuan in the drug R & D project.